EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Stabilizing Plasmodium falciparum proteins for small molecule drug discovery

Marius Amann iD, Tim Sträßer iD, Oliver Einsle iD, Stefan Günther iD

Protein Science · 2026-06 · 35 (6)

DOI: 10.1002/pro.70614 ↗

At a glance

Journal article in Protein Science, published online on 2026-05-02. Written by Marius Amann and 3 co-authors. Institution: Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Freiburg i. Br, Germany. Major MEDLINE topics: Plasmodium falciparum, Protozoan Proteins, Drug Discovery, Antimalarials. Cited 1 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: Deutsche Forschungsgemeinschaft.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Early‐stage drug discovery relies on the availability of stable protein for reliable biophysical characterization of ligand binding. However, many Plasmodium falciparum proteins are challenging to produce in heterologous systems, which limits their experimental utility. To address this, we tested whether ProteinMPNN‐guided sequence design could generate stabilized surrogate constructs that retain wild‐type‐like structure and binding thermodynamics. Designs were generated with constraints to maintain conserved and binding‐site residues for three therapeutically relevant targets: Pf BDP1‐BRD, Pf BDP4‐BRD, and Pf K13‐KREP. The resulting constructs showed markedly increased thermal stability. Using Pf BDP1‐BRD as a benchmark, isothermal titration calorimetry confirmed that the stabilized variants retained wild‐type‐like binding thermodynamics with a known ligand. Extending this approach to other targets, a Pf K13‐KREP construct led to an apo structure with a binding pocket closely matching the wild type. For Pf BDP4‐BRD, virtual screening against a previously reported wild‐type crystal structure identified putative binders, while a stabilized surrogate for this otherwise unstable target enabled their experimental validation and the determination of a 1.25 Å co‐crystal structure with a newly identified inhibitor. Our findings demonstrate that computationally stabilized surrogates are practical and effective tools for robust biophysics and structure‐enabled drug discovery against otherwise challenging malaria proteins.

Subjects

MeSH terms (MEDLINE)

Plasmodium falciparumProtozoan ProteinsDrug DiscoveryAntimalarialsSmall Molecule LibrariesProtein StabilityBinding SitesModels, MolecularThermodynamics

Author keywords

Plasmodium falciparumProteinMPNNdrug discoveryprotein stabilizationx‐ray crystallography

Substances

Protozoan ProteinsAntimalarialsSmall Molecule Libraries

Authors and institutions

  • Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Freiburg i. Br, Germany.
  • Institut für Biochemie, Albert-Ludwigs-Universität Freiburg, Freiburg i. Br, Germany.

ORCID profiles: Marius Amann, Tim Sträßer, Oliver Einsle, Stefan Günther

Funding

  • Deutsche Forschungsgemeinschaft

Cite

APA

Amann, M., Sträßer, T., Einsle, O., & Günther, S. (2026). Stabilizing Plasmodium falciparum proteins for small molecule drug discovery. Protein Science, 35(6). https://doi.org/10.1002/pro.70614

Vancouver

Amann M, Sträßer T, Einsle O, Günther S. Stabilizing Plasmodium falciparum proteins for small molecule drug discovery. Protein Science. 2026;35(6). doi:10.1002/pro.70614

BibTeX
@article{Amann2026,
  author = {Amann, Marius and Sträßer, Tim and Einsle, Oliver and Günther, Stefan},
  title = {Stabilizing Plasmodium falciparum proteins for small molecule drug discovery},
  journal = {Protein Science},
  year = {2026},
  volume = {35},
  number = {6},
  doi = {10.1002/pro.70614}
}
Start for free →